This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/mp4/what-makes-a-good-severe-asthma-referral-john-davison.mp4

Severe Asthma Referrals: This is Real Life


Summary

This webinar has been designed for all healthcare professionals involved in referring severe asthma patients into tertiary care.

In this webinar, you'll hear from severe asthma expert, John Davison. John will be sharing key information about what makes a good severe asthma referral and what is the role of the MDT when a severe asthma patient has been referred.

Speaker

NA

John Davison

Senior Nurse Specialist, The Newcastle upon Tyne Hospitals NHS Foundation Trust

John Davison is the Nurse Specialist for Complex Lung Disease and is based in Newcastle Hospitals NHS Foundation Trust. He has worked in respiratory medicine for over 25 years. Following his ward management role he now specialises in both severe asthma and bronchiectasis. He aims to improve patient outcomes through putting the patient at the centre of their care and promoting shared decision making with an emphasis on improving health literacy.

He is currently deputy chair and administration lead for the northern region severe asthma network and has facilitated and participated in each of the regional severe asthma MDT meetings since 2015.

Alongside his work in bronchiectasis he is responsible for the management of patients receiving biologic treatment in Newcastle and currently focuses on IL5 administration and the patient journey during this treatment.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on +44 (0)800 221 441